0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > All Other Proteins > IL-3 R alpha > ILA-H82F3

Biotinylated Human IL-3 R alpha / CD123 Protein, Fc,Avitag™ (MALS verified)

  • Synonym
    IL3R,IL3RA,IL-3Ra,IL-3R-alpha,IL3RAY,IL3RX,IL3RY,CD123 antigen,CD123,hIL3Ra,hIL-3Ra,MGC34174,IL-3 R alpha
  • Source
    Biotinylated Human IL-3 R alpha, Fc,Avitag (ILA-H82F3) is expressed from human 293 cells (HEK293). It contains AA Thr 19 - Arg 305  (Accession # P26951-1).
    Predicted N-terminus: Thr 19 
  • Molecular Characterization
    Online(Thr 19 - Arg 305 ) P26951-1

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 61.2 kDa. The protein migrates as 80-100 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Biotinylation
    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
  • Biotin:Protein Ratio
    The biotin to protein ratio is 0.5-1 as determined by the HABA assay.
  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >95% as determined by reduced SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Biotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ILA-H82F3) SDS-PAGE gel

Biotinylated Human IL-3 R alpha, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
Biotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ILA-H82F3) was more than 90% and the molecular weight of this protein is around 128-156 kDa verified by SEC-MALS.

Bioactivity-ELISA
Biotinylated Human IL-3 R alpha, Fc,AvitagBiotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ILA-H82F3) ELISA bioactivity

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

Biotinylated Human IL-3 R alpha, Fc,AvitagBiotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ILA-H82F3) ELISA bioactivity

Immobilized Anti-IL-3 R alpha Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ILA-H82F3) with a linear range of 1-20 ng/mL (QC tested).

Biotinylated Human IL-3 R alpha, Fc,AvitagBiotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ILA-H82F3) ELISA bioactivity

Immobilized Biotinylated Human IL-3 R alpha, Fc,Avitag (Cat. No. ILA-H82F3) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-IL-3 R alpha Antibody, Human IgG1 with a linear range of 0.6-5 ng/mL (Routinely tested).

  • Background
    Interleukin 3 receptor alpha (low affinity) (IL3RA), also known as CD123 (Cluster of Differentiation 123) is a 70-kD glycoprotein member of the hematopoietin receptor superfamily. This protein associates with a beta subunit common to the receptors for IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) to form a high-affinity receptor for IL-3. The interleukin-3 receptor α chain (CD123) has been identified as a potential immunotherapeutic target because it is overexpressed in AML compared with normal hematopoietic stem cells.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)

Order Details

Price(USD) : $350.00

Price(USD) : $1380.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:1 Details
  • Number of Drugs in Clinical Trials:19 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Questions & Comments

This web search service is supported by Google Inc.

totop